IPSEN |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 108.4 EUR | +1.98% |
|
-0.91% | +0.46% |
| Apr. 15 | Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights | CF |
| Apr. 02 | Ipsen: worldwide licensing agreement with Sutro Biopharma | CF |
| Sales 2024 * | 3.44B 3.67B | Sales 2025 * | 3.68B 3.92B | Capitalization | 8.95B 9.54B |
|---|---|---|---|---|---|
| Net income 2024 * | 636M 677M | Net income 2025 * | 708M 754M | EV / Sales 2024 * | 2.43 x |
| Net cash position 2024 * | 578M 616M | Net cash position 2025 * | 1.24B 1.32B | EV / Sales 2025 * | 2.1 x |
| P/E ratio 2024 * |
14.2
x | P/E ratio 2025 * |
12.8
x | Employees | 5,325 |
| Yield 2024 * |
1.11% | Yield 2025 * |
1.12% | Free-Float | 41.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ipsen
More press releases
| 1 day | +1.98% | ||
| 1 week | -0.91% | ||
| Current month | -1.72% | ||
| 1 month | +2.65% | ||
| 3 months | +2.17% | ||
| 6 months | -8.29% | ||
| Current year | +0.46% |
1 week
105.30
110.10
1 month
103.90111.50
Current year
99.70111.50
1 year
99.70130.70
3 years
77.00130.70
5 years
34.20130.70
10 years
30.00155.95
| Managers | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director of Finance/CFO | 54 | 14-11-02 | |
| Chairman | 66 | 10-11-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Margaret Liu
BRD | Director/Board Member | 66 | 17-06-06 |
Karen Witts
BRD | Director/Board Member | 61 | 22-01-20 |
Michèle Ollier
BRD | Director/Board Member | 65 | 15-05-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.83% | 2 M€ | +5.72% | ||
| 0.43% | 182 M€ | +3.17% | ||
| 0.31% | 3 M€ | +9.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 108.4 | +1.98% | 61,254 |
| 24-04-18 | 106.3 | -0.09% | 48,574 |
| 24-04-17 | 106.4 | -1.12% | 62,388 |
| 24-04-16 | 107.6 | -0.74% | 54,879 |
| 24-04-15 | 108.4 | -0.91% | 79,894 |
Real-time Euronext Paris, April 19, 2024 at 11:35 am EDT
More quotes
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q1 2024 Sales and Revenue Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
108.4
EUR
Average target price
124.6
EUR
Spread / Average Target
+14.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.46% | 9.36B | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- IPN Stock
